Opinion

Video

The Impact of PSMA-PET Imaging in Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.

Current Time 0:00
Duration 5:51
Loaded: 0%
Stream Type LIVE
Remaining Time 5:51
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
    Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Ruben Olivares, MD, answers a question during a Zoom video interview
    Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    Post-RP incontinence: Low procedure rates examined
    Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
    Data link incontinence severity to post-radical prostatectomy care
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Expert discusses differentiating prostate cancer from age-related issues
    Related Content
    Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
    July 18th 2025

    Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

    Hannah Clarke
    In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
    July 15th 2025

    CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

    Hannah Clarke
    The level II code A9616 will be effective starting on October 1, 2025.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Study shows favorable outcomes with guideline-based treatment for localized prostate cancer
    July 14th 2025

    Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

    Hannah Clarke
    “Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.
    Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    July 10th 2025

    FDA grants breakthrough device designation for ArteraAI Prostate tool

    Benjamin P. Saylor Hannah Clarke
    “This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
    © 2025 MJH Life Sciences

    All rights reserved.